AKTS
Aktis Oncology, Inc. Common stock
stockNASDAQ
founded in 2014 by experienced industry leaders and scientists from university of california at santa barbara (ucsb) and cornell university, akoustis' mission is to commercialize and manufacture its patent-pending bulk one™ acoustic wave technology to address the critical frequency-selectivity requirements in today's mobile smartphones – improving the efficiency and signal quality of mobile wireless devices and enabling the internet of things. the bulk acoustic wave (baw) filter market is rapidly expanding, driven by growth in 4g/lte and the number of filters required per device. nearly 2 billion mobile phones are manufactured per year, and over half are in the growing segment of high-end smartphones. because these smartphones need to operate globally, on more than one carrier, and with bands that are becoming ever-closer together, the need for higher-performance filters is upon us to ensure mobile compatibility. 4g/lte networks are driving the need for higher frequencies, and traditio
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 18.52 | 2026-10-02 | -2.02% | 0.271 |
| 1M | 23.94 | 2026-09-10 | -24.21% | 0.848 |
| 3M | 27.88 | 2026-07-10 | -34.92% | 1.245 |
| 6M | 16.88 | 2026-04-10 | +7.49% | 0.997 |
| 1Y | 22.40 | 2026-01-09 | -19.00% | 1.521 |
| 2Y | 0.08 | 2024-10-10 | +24061.12% | — |
| 5Y | 7.92 | 2021-10-11 | +129.10% | 38.093 |
Aktis Oncology, Inc. Common stock (NASDAQ:AKTS) stock price today is $18.15, and today's volume is 361,043. AKTS is up 2.283% today. The 30 day average volume is 431,659. AKTS market cap is $1.01B with 55.62M shares outstanding.